After discovering possible contamination connected to an unlicensed manufacturing plant in India, the U.S. Food and Drug Administration (FDA) has recalled over 600,000 bottles of the commonly prescribed blood pressure drug ramipril nationwide.
Given that more than 2.4 million Americans use ramipril each year to control high blood pressure by relaxing blood arteries and enhancing cardiovascular health, the recall has caused serious concerns among patients and healthcare professionals.
Lupin Pharmaceuticals produces Ramipril, which comes in three dosage strengths (2.5 mg, 5 mg, and 10 mg) in bottle sizes that hold 90, 100, or 500 capsules. The products in question will expire in July 2026. The 5 mg and 10 mg dosages were the focus of the initial recall, which was declared in October.
The FDA did, however, extend the recall to cover the 2.5 mg strength on November 19. Although no negative consequences have been documented thus far, the FDA has taken precautions to protect public health due to the possibility of contamination.
